MediWound Ltd. (MDWD) - שולי רווח גולמי

MediWound Ltd. maintains an impeccable reputation among surgeons due to the efficacy of NexoBrid. Gross margin fluctuations link this status to fundamental data, where 19.50 represents the latest level value. The company is developing protein purification biotechnologies for tissue regeneration. High scalability is ensured by enzyme patents, allowing the company to supply clinics with minimal production costs per dose.
פילוחים אנליטיים ודוחות נתונים של חברת MediWound Ltd (MDWD)

Selecting high-quality issuers requires analyzing the efficiency of direct cost management through fundamental multiples. Gross margin measures the profit share after deducting the cost of goods sold, reflecting the ability of MediWound Ltd. (MDWD) to monetize its enzymatic wound cleansing automation technologies relative to their production costs, which allows an investor to assess the operational resilience of the business via the gross profitability ratio.